title: What is the optimal duration of bisphosphonate therapy?
abstract: It is reasonable to stop bisphosphonates after 5 years of use and then to follow patients with markers of bone turnover. As long as the levels of these markers remain reduced, adding an antiresorptive drug does not make physiologic sense.
authors: Department of Medicine, University of Washington, Seattle, USA. smott@u.washington.edu
authors: Susan M
authors: SM
authors: Ott
mesh_terms: D019386:Alendronate / Q000627:therapeutic use; D015415:Biomarkers; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005264:Femoral Fractures / Q000209:etiology / Q000517:prevention & control; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D000068296:Risedronic Acid; D012307:Risk Factors; D013997:Time Factors
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate